Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders

AIDS

Volumn 28, Issue 4, 2014, Pages 493-501

  Vassallo, Matteo ^a,b   Durant, Jacques ^a   Biscay, Virginie ^a   Lebrun Frenay, Christine ^c   Dunais, Brigitte ^a   Laffon, Muriel ^c   Harvey Langton, Alexandra ^a   Cottalorda, Jacqueline ^a   Ticchioni, Michel ^a   Carsenti, Helene ^a   Pradier, Christian ^a   Dellamonica, Pierre ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b Cannes General Hospital   (France)

^c Pasteur Hospital   (France)

Author keywords

Antiretroviral Therapy; HIV Associated Neurocognitive Disorders; Neuropsychological Testing

Indexed keywords

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; ASYMPTOMATIC NEUROCOGNITIVE DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; CSF DRUG CONCENTRATION PENETRATION EFFECTIVENESS SCORE; FEMALE; FOLLOW UP; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MIDDLE AGED; MILD NEUROCOGNITIVE DISORDER; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; AGED; AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84893221512     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000096     Document Type: Article

References (26)

1. Mc Arthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus associated neurocognitive disorders: Mind the gap. Ann Neurol 2010; 67:699-714.
2. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21:1915-1921.
3. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009; 19:152-168.
4. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-2096.
5. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25:1747-1751.
6. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
7. Vassallo M, Dunais B, Durant J, Carsenti-Dellamonica H, Harvey-Langton A, Cottalorda J, et al. Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: The Neurdapt study. J Neuroviral 2013; 19:376-382.
8. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. Plos One 2008; 3:e2516.
9. Robertson KR, Su Z, Margolis DM, Krambrink A, Halvir DV, Evans S, et al. Neurocognitive effects of treatment interruption in stable HIVR patients in an observational cohort: ACTG 5170. Neurology 2010; 74:1260-1266.
10. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
11. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al. Dynamics of cognitive change in impaired HIVpositive patients initiating antiretroviral therapies. Neurology 2009; 73:342-348.
12. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
13. Evers S, Rahmann A, Schwaag S, Frese A, Reichelt D, Hussdedt IW. Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid penetrance. AIDS Res Hum Retroviruses 2004; 20:483-491.
14. McCutchan JA,WuJW, Robertson K, Koletar SL, Ellis RJ, Cohn S, et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 2007; 21:1109-1117.
15. The MIND Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): A consensus report of the Mind Exchange Program. Clin Infect Dis 2013; 56:1004-1017.
16. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, et al. Changes in cognition during antiretroviral therapy: Comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52:56-63.
17. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-1799.
18. Letendre S, McClernon D, Ellis R, Munoz-Moreno J, Way L, Franklin D, et al. Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment (Abstract 484b) 16th Conference on Retrovirus and Opportunistic Infections (CROI), 8-11 February 2009, Montreal, Canada.
19. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorders. Top Antivir Med 2011; 19:137-142.
20. Scott JC, Woods SP, Carey CL, Weber E, Bondi MW, Grant I. Neurocognitive consequences of HIV infection in older adults: An evaluation of the cortical hypothesis. AIDS Behav 2010; 15:1187-1196.
21. Ances BM, Vaida F, Yeh MG, Liang CL, Buxton RB, Letendre S, et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis 2011; 201:336-340.
22. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243-1250.
23. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: Are we overestimating the real prevalence BMC 2011; 11:356.
24. Torti C, Focà E, Cesana BM, Lescure FX. Asymptomatic neurocognitive disorders in patients infected by HIV: Fact or fiction BMC 2011; 9:138.
25. Shikuma CM, Nakamoto B, Shiramizu B, Liang CY, DeGruttola V, Bennet K, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antiviral Ther 2012; 17:1233-1242.
26. Price RW, Swanson R. Targeting chronic central nervous system HIV infection. Antiviral Ther 2012; 17:1227-1231.